Here’s a startling truth: the weight you lose on popular obesity drugs can come rushing back faster than you’d expect once you stop taking them. But here’s where it gets controversial—while these medications have been hailed as game-changers for obesity and diabetes, new research reveals a surprising twist in their long-term effectiveness. A groundbreaking study published in the BMJ found that individuals regain weight at a staggering four times the rate after discontinuing these drugs compared to those who rely solely on diet and exercise. And this is the part most people miss—it’s not just about the speed of weight regain; it’s about what this means for the future of obesity treatment.
The spotlight is on a new class of injectable drugs called GLP-1 agonists, which have taken the medical world by storm in recent years. These medications, including brands like Ozempic, Wegovy, Mounjaro, and Zepbound, have shown remarkable results, helping users shed between 15% to 20% of their body weight. Susan Jebb, a public health nutrition scientist at Oxford University and co-author of the study, initially called this a ‘good news story.’ But the narrative takes a turn when you dig deeper.
Recent data suggests that nearly half of users stop taking these drugs within a year. Why? Common side effects like nausea and the hefty price tag—over $1,000 per month in the U.S.—are likely culprits. The study reviewed 37 trials and found that participants regained about 0.4 kilograms per month after stopping the medication. For those on semaglutide or tirzepatide, the two most popular drugs, the numbers are even more striking: after losing nearly 15 kilograms on average, they regained 10 kilograms within a year. Researchers predict a return to the original weight within 18 months. Even heart health markers, like blood pressure and cholesterol, reverted to baseline levels after just 1.4 years.
In contrast, individuals relying on diet and exercise lost less weight initially but took an average of four years to regain it. This raises a critical question: Are these drugs a sustainable solution, or just a temporary fix? Here’s the bold part—lead author Sam West points out that while greater weight loss often leads to faster regain, the data shows that medication users regain weight more rapidly regardless of how much they initially lost. This suggests that lifestyle changes, like healthier eating and regular exercise, may offer a more enduring impact, even during weight regain.
Susan Jebb emphasizes that GLP-1 drugs are ‘a really valuable tool,’ but obesity is a chronic, relapsing condition. ‘These treatments may need to be continued for life, just like blood pressure medication,’ she notes. This has massive implications for healthcare systems evaluating their cost-effectiveness. Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne, sums it up: ‘This new data makes it clear they are a starting point, not a cure.’ He argues that sustainable treatment will require a combination of approaches, long-term strategies, and therapies that address the brain’s interpretation of energy balance, not just calorie intake.
Now, here’s the thought-provoking question for you: If these drugs require lifelong use to maintain results, should they be considered a cure for obesity, or are they just another tool in a much larger battle? Share your thoughts in the comments—do you think the benefits outweigh the costs, or is there a better way forward?
